API | gp-100 peptide vaccine

gp-100 peptide vaccine Report issue

Vaccine Experimental

AACT PubChem

Active Ingredient History

NOW

Glycoprotein 100, gp100 or Melanocyte protein PMEL is 661 amino acids long and is a type I transmembrane glycoprotein enriched in melanosomes, which are the melanin-producing organelles in melanocytes. This protein is involved in melanosome maturation. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Melanocyte protein PMEL (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

alvac gp100 vaccine | anti-gp100:154-162 tcell receptor peripheral blood lymphocyte | glycoprotein 100 | gp100 | gp100:154-162 | gp100: 209-217 | gp100:209-217 | gp100:280-288 | gp-100 peptide vaccine | human gp100 plasmid dna vaccine | mouse gp100 plasmid dna vaccine

Organizations (26)

Research & Development (26)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (1)

Melanoma

Experimental Indications - Clinical Trial Phases 1-4 (4)

Carcinoma, Renal Cell (Phase 2)

Melanoma (Phase 3)

Neoplasm Metastasis (Phase 2)

Skin Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 58
# of Trial Organizations: 26

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue